Ein Paarvergleich findet Originalpassagen, die den anderen Wirkstoff wörtlich nennen. Aussagen gelten für das jeweilige Präparat und seine Formulierung. Klassenbegriffe und abweichende Synonyme können fehlen. Kein Treffer bedeutet nicht, dass keine Wechselwirkung besteht.
RxNorm 05-Oct-2026 · geprüft 2026-10-25 · 1009 Präparate · 54812 Quellenpassagen · 148 strukturierte Aussagen. Automatisch aktualisiert, ohne menschliche Freigabe.
Wechselwirkungen · Ketoconazole Esteve (previously Ketoconazole HRA)
Ketoconazole Esteve 200 mg tablets · Abschnitt 4.5 · PDF-Seite 7
HOS-132847 · Präparat HOS-097310
Ketoconazole is mainly metabolised by cytochrome CYP3A4.
Enzyme-inducing medicinal products such as rifampicin, rifabutin, carbamazepine, isoniazid, nevirapine,
mitotane and phenytoin may significantly reduce the bioavailability of ketoconazole. Use of ketoconazole with
potent enzyme inducers is not recommended.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): carbamazepine (HOS-085618) rifabutin (HOS-086262) mitotane (HOS-112479) nevirapine (HOS-088064) isoniazid (HOS-088590) phenytoin (HOS-084531)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-05-05T12:00:00Z · SHA-256 1463d2e081bcaa454cdfd6129ad3b8e03e3df9233f9d0704cfceba71c89c59b5 · Passage 8438e2557ee1bbba4af94523b7f8fd21331bb2f8e99ca2dc95c8883b5c86c5e8 · Zeichen 2486–2799 im Abschnitt
Wechselwirkungen · Ketoconazole Esteve (previously Ketoconazole HRA)
Ketoconazole Esteve 200 mg tablets · Abschnitt 4.5 · PDF-Seite 8–9
HOS-132855 · Präparat HOS-097310
8
Medicinal product by Expected effect on drug levels Recommendation for co-
therapeutic area administration
Digoxin Potential ↑in plasma concentrations of Careful monitoring of digoxin levels
digoxine is recommended.
Anticoagulants and
antiplatelet drugs
Dabigatran Dabigatran: Contraindicated due to an increased
AUC: ↑ 2.6-fold bleeding risk (see section 4.3).
Cmax: ↑2.5-fold
Rivaroxaban Rivaroxaban: Not recommended due to an
AUC: ↑ 2.6-fold increased bleeding risk.
Cmax: ↑1.7-fold
Apixaban Apixaban Not recommended due to an
AUC: ↑ 2-fold increased bleeding risk.
Cmax: ↑1.6-fold
Cilostazol Cilostazol: Careful monitoring
AUC: ↑ 2.2 fold A cilostazol dose of 50 mg twice
daily is recommended in combination
The overall pharmacological activity of with ketoconazole.
cilostazol increases 35% when co-
administered with ketoconazole.
Warfarin and other Potential ↑in plasma concentrations of Careful monitoring
coumarin-like drugs warfarin INR (international normalised ratio)
monitoring recommended.
Edoxaban AUC: ↑ 1.8-fold Dose of edoxaban needs to be
Cmax: ↑ 1.8-fold reduced when used concomitantly,
please consult edoxaban SmPC.
Anticonvulsants
Carbamazepine Potential ↑in plasma concentrations of Not recommended.
Phenytoin carbamazepine and phenytoin (See also “Effects of other medicinal
products on the metabolism of
Potential ↓ in plasma concentrations of Ketoconazole Esteve ”).
ketoconazole are expected.
(CYP3A enzyme induction)
Antidiabetics
Repaglinide Repaglinide: Careful monitoring.
AUC: ↑ 1.2-fold Dose adjustement of repaglinide may
Cmax: ↑ 1.2-fold be required.
Saxagliptin Saxagliptin: Careful monitoring.
AUC: ↑ 2.5-fold Dose adjustment of saxagliptin may
Cmax: ↑ 1.6-fold be required.
Associated with a decrease in
corresponding values for the active
metabolite
Tolbutamide Tolbutamide: Careful monitoring.
AUC: ↑ 1.7-fold Dose adjustment of tolbutamide may
be required.
Anti-infectives
Rifabutin Potential ↑ in plasma concentrations of Not recommended. (See also “Effects
Rifampicin rifabutine. of other medicinal products on the
Isoniazid Potencial ↓ in plasma concentrations of metabolism of Ketoconazole Esteve
ketoconazole are expected. ”)
(CYP3A4 enzyme induction)
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): cilostazol (HOS-111550) saxagliptin (HOS-121455) carbamazepine (HOS-085618) rifabutin (HOS-086262) digoxin (HOS-086172) dabigatran (HOS-112096) rivaroxaban (HOS-086236) edoxaban (HOS-086234) apixaban (HOS-112091) isoniazid (HOS-088590) phenytoin (HOS-084531) warfarin (HOS-085950) repaglinide (HOS-086935) tolbutamide (HOS-086568)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-05-05T12:00:00Z · SHA-256 1463d2e081bcaa454cdfd6129ad3b8e03e3df9233f9d0704cfceba71c89c59b5 · Passage 24d8b798c2e9f588393126dccbf62410ab1c9fc1c2be502385d6b5856457931a · Zeichen 7545–11521 im Abschnitt
Wechselwirkungen · Suliqua
Suliqua 100 units/ml + 50 micrograms/ml solution for injection in pre-filled pen Suliqua 100 units/ml + 33 micrograms/ml solution for injection in pre-filled pen · Abschnitt 4.5 · PDF-Seite 7
HOS-136758 · Präparat HOS-097920
Substances that may reduce the blood-glucose-lowering effect include corticosteroids, danazol,
diazoxide, diuretics, glucagon, isoniazid, oestrogens and progestogens, phenothiazine derivatives,
somatropin, sympathomimetic medicinal products (e.g., epinephrine [adrenaline], salbutamol,
terbutaline), thyroid hormones, atypical antipsychotic medicinal products (e.g., clozapine and
olanzapine) and protease inhibitors.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): olanzapine (HOS-085937) protease (HOS-085623) diazoxide (HOS-088588) danazol (HOS-085473) somatropin (HOS-088591) epinephrine (HOS-088592) clozapine (HOS-086149) terbutaline (HOS-085475) isoniazid (HOS-088590) glucagon (HOS-088589)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-09-08T12:17:00Z · SHA-256 dc49151049b984e91c1de4b6624055f9c88998d89821408c31acf9bbdf9d1734 · Passage 192500b863b13435d4abfa5e828836106445012113b370397ddfddd94fa2cbbc · Zeichen 603–1020 im Abschnitt
Wechselwirkungen · Tacforius
Tacforius 0.5 mg prolonged-release hard capsules Tacforius 1 mg prolonged-release hard capsules Tacforius 3 mg prolonged-release hard capsules Tacforius 5 mg prolonged-release hard capsules · Abschnitt 4.5 · PDF-Seite 12–13
HOS-139170 · Präparat HOS-098290
12
Drug/Substance Class or Drug interaction effect Recommendations concerning
Name co-administration
In vitro the following May increase tacrolimus whole Monitor tacrolimus whole
substances have been shown blood trough concentrations and blood trough concentrations
to be potential inhibitors of increase the risk of serious adverse and reduce tacrolimus dose if
tacrolimus metabolism: reactions (e.g., neurotoxicity, QT needed (see section 4.2).
bromocriptine, cortisone, prolongation) (see section 4.4). Monitor renal function, ECG
dapsone, ergotamine, for QT prolongation, and other
gestodene, lidocaine, side effects closely.
mephenytoin, midazolam,
nilvadipine, norethisterone,
quinidine, tamoxifen.
Strong CYP3A4 inducers: May decrease tacrolimus whole It is recommended that
rifampicin, phenytoin, blood trough concentrations and concomitant use should be
carbamazepine, apalutamide, increase the risk of rejection (see avoided. If unavoidable,
enzalutamide, mitotane, or St. section 4.4). patients may require an
John’s wort (Hypericum Maximal effect on tacrolimus blood increase in tacrolimus dose.
perforatum) concentrations may be achieved 1-2 Changes in tacrolimus dose
weeks after co-administration. The should be individualized and
effect may remain 1-2 weeks after adjusted as needed based on
completion of the treatment. tacrolimus trough
concentrations, which should
be assessed at initiation,
monitored frequently
throughout (starting within the
first few days) and re-
evaluated on and after
completion of the CYP3A4
inducer. After use of the
CYP3A4 inducer has ended,
tacrolimus dose may need to
be adjusted gradually. Monitor
graft function closely.
Moderate CYP3A4 inducers: May decrease tacrolimus whole Monitor tacrolimus whole
metamizole, phenobarbital, blood trough concentrations and blood trough concentrations
isoniazid, rifabutin, efavirenz, increase the risk of rejection (see and increase tacrolimus dose if
etravirine, nevirapine section 4.4). needed (see section 4.2).
Weak CYP3A4 inducers: Monitor graft function closely.
flucloxacillin
Caspofungin May decrease tacrolimus whole Monitor tacrolimus whole
blood trough concentrations and blood trough concentrations
increase the risk of rejection. and increase tacrolimus dose if
Mechanism of interaction has not needed (see section 4.2).
been confirmed. Monitor graft function closely.
Cannabidiol (P-gp inhibitor) There have been reports of Tacrolimus and cannabidiol
increased tacrolimus blood levels should be co-administered with
during concomitant use of caution, closely monitoring for
tacrolimus with cannabidiol. This side effects. Monitor
may be due to inhibition of tacrolimus whole blood trough
intestinal P-glycoprotein, leading to concentrations and adjust the
increased bioavailability of tacrolimus dose if needed (see
tacrolimus. sections 4.2 and 4.4).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): cortisone (HOS-114161) caspofungin (HOS-109306) phenobarbital (HOS-085617) lidocaine (HOS-108866) carbamazepine (HOS-085618) rifabutin (HOS-086262) apalutamide (HOS-086212) tamoxifen (HOS-088380) quinidine (HOS-085593) etravirine (HOS-088088) mephenytoin (HOS-109801) cannabidiol (HOS-090609) mitotane (HOS-112479) bromocriptine (HOS-090620) efavirenz (HOS-087947) nilvadipine (HOS-116826) gestodene (HOS-116824) nevirapine (HOS-088064) ergotamine (HOS-086154) isoniazid (HOS-088590) dapsone (HOS-088141) phenytoin (HOS-084531) enzalutamide (HOS-116829) midazolam (HOS-086167)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-05-08T17:10:00Z · SHA-256 bf71e479a3104e9d8dd9aede574f2baf87c2d76cd8cc9266ee2ef92ed475dc55 · Passage fa1f35020c5c33f04f1dedfbde5310972baf1c60d65f0f37f47f320487c85aab · Zeichen 8700–13685 im Abschnitt
Wechselwirkungen · Inbrija
Inbrija 33 mg inhalation powder, hard capsules · Abschnitt 4.5 · PDF-Seite 5
HOS-142003 · Präparat HOS-098736
Dopamine D2 receptor antagonists and isoniazid
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): dopamine (HOS-085948) isoniazid (HOS-088590)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-12-09T16:00:00Z · SHA-256 8efbaf885ca07144006263a202c7c665fe11b3f45faa6d3a3dd8a889b096ca73 · Passage c97ddfa3439bd8102837329646d520a7c71ce7c320d5fc29133ef5db0465a5ef · Zeichen 518–564 im Abschnitt
Wechselwirkungen · Inbrija
Inbrija 33 mg inhalation powder, hard capsules · Abschnitt 4.5 · PDF-Seite 5
HOS-142006 · Präparat HOS-098736
Dopamine D2 receptor antagonists (e.g. phenothiazines, butyrophenones, risperidone,
metoclopramide) and isoniazid may reduce the effectiveness of levodopa. Patients who are taking
these medicinal products should be monitored for worsening Parkinson’s symptoms (see section 4.4).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): dopamine (HOS-085948) risperidone (HOS-086280) metoclopramide (HOS-090626) isoniazid (HOS-088590)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-12-09T16:00:00Z · SHA-256 8efbaf885ca07144006263a202c7c665fe11b3f45faa6d3a3dd8a889b096ca73 · Passage f1649f88664919c76b7fce9d365e303ffdd9d5d2f50047872edf249ac7e24ce7 · Zeichen 566–844 im Abschnitt
Wechselwirkungen · Onerji
Onerji (60 mg + 7.5 mg)/mL solution for infusion · Abschnitt 4.5 · PDF-Seite 8
HOS-152952 · Präparat HOS-100875
Dopamine D2 receptor antagonists and isoniazid
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): dopamine (HOS-085948) isoniazid (HOS-088590)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-09-23T10:32:00Z · SHA-256 0a3b093da64a9acdd1634c12578cb8b735dccbd1f74b12bfa050312b0763b0d8 · Passage c97ddfa3439bd8102837329646d520a7c71ce7c320d5fc29133ef5db0465a5ef · Zeichen 1783–1829 im Abschnitt
Wechselwirkungen · Onerji
Onerji (60 mg + 7.5 mg)/mL solution for infusion · Abschnitt 4.5 · PDF-Seite 8
HOS-152955 · Präparat HOS-100875
Dopamine D2 receptor antagonists (e.g. phenothiazines, butyrophenones, risperidone and
metoclopramide), and isoniazid, may reduce the therapeutic effect of levodopa. Monitor patients for
worsening of Parkinson’s disease symptoms.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): dopamine (HOS-085948) risperidone (HOS-086280) metoclopramide (HOS-090626) isoniazid (HOS-088590)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-09-23T10:32:00Z · SHA-256 0a3b093da64a9acdd1634c12578cb8b735dccbd1f74b12bfa050312b0763b0d8 · Passage 033aa4f9bdbe97f1b9831ebd75e7a519879e9e1711a17839c159337cf1b9cbd0 · Zeichen 1831–2060 im Abschnitt
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.